IPSEN S.A. PORT. EO 1/ FR0010259150 /
2024-05-31 3:41:55 PM | Chg. +1.400 | Volume | Bid10:00:01 PM | Ask10:00:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
119.300EUR | +1.19% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 10.11 bill.EUR | 1.00% | 15.48 |
GlobeNewswire
04-24
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire
04-22
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire
04-02
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire
02-13
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire
2023-12-07
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire
2023-12-07
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...
GlobeNewswire
2023-11-13
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire
2023-10-26
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...
GlobeNewswire
2023-10-23
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire
2023-09-04
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswire
2023-09-01
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
GlobeNewswire
2023-08-21
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Caboza...
GlobeNewswire
2023-08-16
US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people w...
GlobeNewswire
2015-04-16
Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in pr...
GlobeNewswire
2013-10-09
Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study
GlobeNewswire
2013-04-25
Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in t...
GlobeNewswire
2012-12-10
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study ...